ArticleNutrients2024
Synergistic Effect of β-Cryptoxanthin and Epigallocatechin Gallate on Obesity Reduction.
Article in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Integrative Roles of Functional Foods, Microbiotics, Nutrigenetics, and Nutrigenomics in Managing Type 2 Diabetes and Obesity.Nutrients · 2025Pooled it
- Repositioning Natural Products in Modern Drug Discovery: Technological Innovation, Systems Pharmacology, and Pathological Validation.International journal of molecular sciences · 2026Review
- Vitamin A Derivatives and Adipose Tissue Differentiation: Molecular Pathways Driving Browning and Anti-Obesity Effects.Current obesity reports · 2026Review
- Epigallocatechin-Gallate (EGCG): An Essential Molecule for Human Health and Well-Being.International journal of molecular sciences · 2025Review
- The Interplay Between Oxidative Stress and Lipid Composition in Obesity-Induced Inflammation: Antioxidants as Therapeutic Agents in Metabolic Diseases.International journal of molecular sciences · 2025Review
- Anti-Inflammatory Actions of Plant-Derived Compounds and Prevention of Chronic Diseases: From Molecular Mechanisms to Applications.International journal of molecular sciences · 2025Review
- Carotenoids for Antiaging: Nutraceutical, Pharmaceutical, and Cosmeceutical Applications.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chronic obesity is an alarmingly growing global public health concern, posing substantial challenges for the prevention of chronic diseases, including hyperinsulinemia, type 2 diabetes, hyperlipidemia, hypertension, and coronary artery disease, and there is an urgent need for early mitigation strategies. We previously reported the obesity-reducing effects of green tea and β-cryptoxanthin intake. However, since tea has a complex mixture of compounds, it remained unclear which component contributed the most to this effect. Using high-performance liquid chromatography, we analyzed the components of tea in this study to determine if consumption of any combination of these compounds with β-cryptoxanthin had an obesity-reducing effect. Consuming epigallocatechin gallate (EGCG), a component of green tea, and β-cryptoxanthin for 4 weeks led to a decrease in body weight. Moreover, the weight and size of the white adipose tissues were significantly reduced, and blood biochemistry test results were comparable to normal values, with particular improvement in liver function. This indicated that intake of EGCG and β-cryptoxanthin reduces obesity in both subcutaneous and visceral fat. These findings suggest that simultaneous intake of EGCG and β-cryptoxanthin not only reduces obesity but also has a systemic beneficial effect on the body's normal physiological function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.